A group of donors and partners is racing to ensure a breakthrough HIV prevention drug is inexpensive and broadly accessible.
Lenacapavir, a preexposure prophylaxis injection, or PrEP, which offers protection for six months before another shot is needed, has shown nearly perfect efficacy in preventing HIV transmission and generated high levels of excitement around its potential to help hasten the epidemic’s end.
Under two separate partnerships, both announced Wednesday at the United Nations General Assembly, India-based generic manufacturers are expected to produce the new injection at $40 per person per year for 120 low- and middle-income countries by as early as 2027 — that’s the same price as a year’s course of daily oral PrEP.
Printing articles to share with others is a breach of our terms and conditions and copyright policy. Please use the sharing options on the left side of the article. Devex Pro members may share up to 10 articles per month using the Pro share tool ( ).
About the author
Sara Jervingsarajerving
Sara Jerving is a Senior Reporter at Devex, where she covers global health. Her work has appeared in The New York Times, the Los Angeles Times, The Wall Street Journal, VICE News, and Bloomberg News among others. Sara holds a master's degree from Columbia University Graduate School of Journalism where she was a Lorana Sullivan fellow. She was a finalist for One World Media's Digital Media Award in 2021; a finalist for the Livingston Award for Young Journalists in 2018; and she was part of a VICE News Tonight on HBO team that received an Emmy nomination in 2018. She received the Philip Greer Memorial Award from Columbia University Graduate School of Journalism in 2014.
